Relmada Therapeutics To Present At The Biotech Showcase™ 2013 Relmada Therapeutics will present its recent progress and an update of the development plan of its lead drug candidates to investors and biotech industry executives.
BLUE BELL, Pa., Jan. 4, 2013 /PRNewswire/ -- Relmada Therapeutics, a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that Sergio Traversa, the company's Chief Executive Officer, will be presenting at the Biotech Showcase in San Francisco on Tuesday, January 8, 2013 at 1:45 PM Pacific Time.
The presentation will include an overview of Relmada business and an update on the ongoing development programs of LevoCap, d-methadone, MepiGel and BuTab for the treatment of various forms of chronic pain.
The Biotech Showcase is being held at the Parc 55 Wyndham Union Square Hotel in San Francisco and it provides private and public life science companies the opportunity to present to an audience of investors and business development executives.
About Relmada Therapeutics
Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company focused on developing both novel versions of proven drugs and new molecules that potentially address high unmet medical needs in the treatment of chronic pain. The Company has a deep and diversified portfolio of four lead productsat different stages of development and an early stage pipeline of an additional three products. Our executive offices are located at 138 Canterbury Lane, Blue Bell, PA 19422 and our phone number is 917 405 1305.
Visit our website at www.relmada.com
SOURCE Relmada Therapeutics, Inc.